Limb Salvage

The FDA granted orphan drug designation to CLBS12, an investigational nongene-edited cell therapy for the treatment of Buerger’s disease, according to the agent’s manufacturer.

The first thing she asked was, “Is my husband going to get to come?”

Healio and Cardiology Today have aggregated the most-read news from the virtual VIVA 20.

In the single-arm PROMISE I study of deep venous arterialization in patients with severe critical limb ischemia, seven of 10 survived and were free from amputation at 1 year, according to data presented at the virtual VIVA 20.

In a pooled analysis of three single-center studies, a bioresorbable scaffold was associated with high rates of patency and low rates of adverse events at 2 years in high-risk patients with infrapopliteal artery lesions.

Critical limb ischemia, also known as chronic limb-threatening ischemia, is an undertreated disease that often leads to amputation and/or mortality. One reason for undertreatment and underdiagnosis was coding.

September is Peripheral Artery Disease Awareness Month, designed to improve access to screening and treatments for patients with PAD.

The increased occurrence of total femoral replacement failure reinforces that this procedure must only be undertaken once all other options have been exhausted, according to investigators of a recently published study.

LAS VEGAS — A bioresorbable scaffold was shown to be safe and effective for treatment of below-the-knee lesions in two studies presented at VIVA 19.

LAS VEGAS — While critical limb ischemia presents many challenges, numerous new technologies and techniques are being developed to help this population, Peter Schneider, MD, said at VIVA 19.